(ROP) Roper Technologies - Overview

Sector: Technology | Industry: Software - Application | Exchange: NASDAQ (USA) | Market Cap: 37.320m USD | Total Return: -39.9% in 12m

Stock Software, Analytics, Payments, Medical, Sensors
Total Rating 26
Risk 80
Buy Signal -0.67
Software - Application +12.3
Industrial Conglomerates +0.1
Market Cap: 37,320m
Avg Trading Vol: 475M USD
ATR: 2.77%
Peers RS (IBD): 3.8
Risk 5d forecast
Volatility20.7%
Rel. Tail Risk2.02%
Reward TTM
Sharpe Ratio-2.01
Alpha-47.76
Character TTM
Beta0.389
Beta Downside0.453
Drawdowns 3y
Max DD46.51%
CAGR/Max DD-0.14
EPS (Earnings per Share) EPS (Earnings per Share) of ROP over the last years for every Quarter: "2021-03": 3.6, "2021-06": 3.76, "2021-09": 3.91, "2021-12": 3.73, "2022-03": 3.77, "2022-06": 3.95, "2022-09": 3.67, "2022-12": 3.92, "2023-03": 3.9, "2023-06": 4.12, "2023-09": 4.32, "2023-12": 4.37, "2024-03": 4.41, "2024-06": 4.48, "2024-09": 4.62, "2024-12": 4.81, "2025-03": 4.78, "2025-06": 4.87, "2025-09": 5.14, "2025-12": 5.21, "2026-03": 0,
EPS CAGR: -45.88%
EPS Trend: -25.4%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of ROP over the last years for every Quarter: 2021-03: 1376.1, 2021-06: 1189.8, 2021-09: 1232.1, 2021-12: 1256.6, 2022-03: 1279.8, 2022-06: 1310.8, 2022-09: 1350.3, 2022-12: 1430.9, 2023-03: 1469.7, 2023-06: 1531.2, 2023-09: 1563.4, 2023-12: 1613.5, 2024-03: 1680.7, 2024-06: 1716.8, 2024-09: 1764.6, 2024-12: 1877.1, 2025-03: 1882.8, 2025-06: 1943.6, 2025-09: 2017.5, 2025-12: 2058.6, 2026-03: null,
Rev. CAGR: 13.51%
Rev. Trend: 99.7%
Last SUE: -1.14
Qual. Beats: 0
Description: ROP Roper Technologies March 02, 2026

Roper Technologies (NASDAQ: ROP) is a diversified industrial conglomerate that creates vertical-market software and technology-enabled products across North America, Europe and Asia. Its portfolio spans Application Software (e.g., K-12 administration, transportation and insurance analytics), Network Software (cloud collaboration, supply-chain and health-care solutions) and Technology-Enabled Products (medical devices, precision measurement tools, RFID and water-metering equipment), plus a niche autism-and-IDD care platform.

In its most recent fiscal year, ROP delivered $6.5 billion of revenue, an 8 % year-over-year increase, and generated $1.2 billion of free cash flow, supporting a 15.5 % operating margin and a 12 % rise in adjusted EPS to $5.20. The company maintained a 0.8 % dividend yield and repurchased $500 million of shares, underscoring strong cash generation. Key drivers include accelerating adoption of cloud-based software in health-care and insurance, continued industrial automation spending, and robust demand for precision measurement and sensor solutions in infrastructure projects.

For a deeper dive, you might explore ValueRay’s analysis of ROP to see how these trends could shape its future performance.

Headlines to Watch Out For
  • Software segment growth drives revenue expansion
  • Acquisition strategy fuels portfolio diversification
  • Healthcare technology demand boosts product sales
  • Cloud-based solutions increase recurring revenue
Piotroski VR‑10 (Strict, 0-10) 5.5
Net Income: 1.54b TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.11 > 1.0
NWC/Revenue: -22.75% < 20% (prev -32.53%; Δ 9.78% < -1%)
CFO/TA 0.07 > 3% & CFO 2.54b > Net Income 1.54b
Net Debt (9.00b) to EBITDA (3.36b): 2.68 < 3
Current Ratio: 0.52 > 1.5 & < 3
Outstanding Shares: last quarter (107.8m) vs 12m ago -0.28% < -2%
Gross Margin: 69.24% > 18% (prev 0.69%; Δ 6.86k% > 0.5%)
Asset Turnover: 23.98% > 50% (prev 22.46%; Δ 1.51% > 0%)
Interest Coverage Ratio: 6.96 > 6 (EBITDA TTM 3.36b / Interest Expense TTM 325.0m)
Altman Z'' 2.96
A: -0.05 (Total Current Assets 1.93b - Total Current Liabilities 3.73b) / Total Assets 34.58b
B: 0.50 (Retained Earnings 17.21b / Total Assets 34.58b)
C: 0.07 (EBIT TTM 2.26b / Avg Total Assets 32.96b)
D: 1.16 (Book Value of Equity 17.11b / Total Liabilities 14.70b)
Altman-Z'' Score: 2.96 = A
Beneish M -2.91
DSRI: 1.08 (Receivables 1.25b/1.04b, Revenue 7.90b/7.04b)
GMI: 1.00 (GM 69.24% / 69.30%)
AQI: 0.99 (AQ_t 0.94 / AQ_t-1 0.95)
SGI: 1.12 (Revenue 7.90b / 7.04b)
TATA: -0.03 (NI 1.54b - CFO 2.54b) / TA 34.58b)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of ROP shares? As of March 31, 2026, the stock is trading at USD 351.96 with a total of 1,226,867 shares traded.
Over the past week, the price has changed by -0.43%, over one month by +0.64%, over three months by -21.64% and over the past year by -39.91%.
Is ROP a buy, sell or hold? Roper Technologies has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy ROP.
  • StrongBuy: 10
  • Buy: 2
  • Hold: 6
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the ROP price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 462.2 31.3%
Analysts Target Price 462.2 31.3%
ROP Fundamental Data Overview March 27, 2026
P/E Trailing = 24.3826
P/E Forward = 16.5837
P/S = 4.7226
P/B = 1.831
P/EG = 1.565
Revenue TTM = 7.90b USD
EBIT TTM = 2.26b USD
EBITDA TTM = 3.36b USD
Long Term Debt = 8.60b USD (from longTermDebt, last quarter)
Short Term Debt = 705.2m USD (from shortTermDebt, last quarter)
Debt = 9.30b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.00b USD (from netDebt column, last quarter)
Enterprise Value = 46.32b USD (37.32b + Debt 9.30b - CCE 297.4m)
Interest Coverage Ratio = 6.96 (Ebit TTM 2.26b / Interest Expense TTM 325.0m)
EV/FCF = 18.58x (Enterprise Value 46.32b / FCF TTM 2.49b)
FCF Yield = 5.38% (FCF TTM 2.49b / Enterprise Value 46.32b)
FCF Margin = 31.55% (FCF TTM 2.49b / Revenue TTM 7.90b)
Net Margin = 19.44% (Net Income TTM 1.54b / Revenue TTM 7.90b)
Gross Margin = 69.24% ((Revenue TTM 7.90b - Cost of Revenue TTM 2.43b) / Revenue TTM)
Gross Margin QoQ = 69.46% (prev 69.54%)
Tobins Q-Ratio = 1.34 (Enterprise Value 46.32b / Total Assets 34.58b)
Interest Expense / Debt = 1.00% (Interest Expense 93.3m / Debt 9.30b)
Taxrate = 19.87% (106.2m / 534.6m)
NOPAT = 1.81b (EBIT 2.26b * (1 - 19.87%))
Current Ratio = 0.52 (Total Current Assets 1.93b / Total Current Liabilities 3.73b)
Debt / Equity = 0.47 (Debt 9.30b / totalStockholderEquity, last quarter 19.88b)
Debt / EBITDA = 2.68 (Net Debt 9.00b / EBITDA 3.36b)
Debt / FCF = 3.61 (Net Debt 9.00b / FCF TTM 2.49b)
Total Stockholder Equity = 19.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.66% (Net Income 1.54b / Total Assets 34.58b)
RoE = 7.81% (Net Income TTM 1.54b / Total Stockholder Equity 19.68b)
RoCE = 8.00% (EBIT 2.26b / Capital Employed (Equity 19.68b + L.T.Debt 8.60b))
RoIC = 6.37% (NOPAT 1.81b / Invested Capital 28.45b)
WACC = 6.04% (E(37.32b)/V(46.62b) * Re(7.35%) + D(9.30b)/V(46.62b) * Rd(1.00%) * (1-Tc(0.20)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.05%
[DCF] Terminal Value 87.42% ; FCFF base≈2.41b ; Y1≈2.77b ; Y5≈3.86b
[DCF] Fair Price = 994.8 (EV 111.40b - Net Debt 9.00b = Equity 102.39b / Shares 102.9m; r=6.04% [WACC]; 5y FCF grow 17.15% → 3.0% )
EPS Correlation: -25.43 | EPS CAGR: -45.88% | SUE: -4.0 | # QB: 0
Revenue Correlation: 99.73 | Revenue CAGR: 13.51% | SUE: -1.14 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.28 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-3 | Analysts=17
EPS current Year (2026-12-31): EPS=21.46 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-5 | Growth EPS=+7.3% | Growth Revenue=+7.6%
EPS next Year (2027-12-31): EPS=23.33 | Chg7d=-0.115 | Chg30d=-0.337 | Revisions Net=-4 | Growth EPS=+8.7% | Growth Revenue=+7.0%
[Analyst] Revisions Ratio: -0.27 (4 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +4.2% (Analyst 8.1% - Implied 3.8%)
Additional Sources for ROP Stock Fund Manager Positions: Dataroma · Stockcircle